文献速递肝病

慢性肝病中疲劳的评估及其影响

Assessment of fatigue and its impact in chronic liver disease.
PubMed 文献 · J Hepatol · 2024-04-24

慢性肝病患者的健康相关生活质量(HRQL)和疲劳等患者报告结局(PRO)是重要结局指标。肝硬化与晚期肝病与HRQL恶化和疲劳相关,但部分早期患者也出现疲劳。专家组综述了原发性胆汁性胆管炎、丙型肝炎病毒和MASLD中疲劳与HRQL的概念,指出疲劳包含外周和中枢原因,丙型肝炎和MASLD治疗可改善疲劳和HRQL,而原发性胆汁性胆管炎现有治疗似乎不影响疲劳水平。

要点

  • 疲劳包含外周(神经肌肉衰竭,常伴次极量心肺功能)和中枢(中枢神经系统功能障碍)原因。
  • 疲劳和HRQL通过经过验证的自我报告工具测量,也可通过握力等客观测试测量。
  • 丙型肝炎和MASLD的治疗可改善疲劳水平和HRQL,而原发性胆汁性胆管炎现有治疗似乎不影响疲劳水平。

核心结论

  • 获取包括HRQL和疲劳在内的PRO数据对于确定慢性肝病及其潜在治疗的全面负担至关重要。

研究设计与样本

  • 由疲劳和慢性肝病领域的专家组对文献进行回顾和讨论,合作提供关于慢性肝病疲劳的专家综述。

主要发现

  • 肝硬化和晚期肝病与HRQL恶化和疲劳相关。
  • 部分早期慢性肝病患者也经历疲劳,导致PRO受损。
  • 疲劳对HRQL以及身体活动和社会参与能力有不良影响,但不总是与慢性肝病严重程度相关。
  • 丙型肝炎病毒和MASLD的治疗可改善疲劳水平和HRQL。
  • 原发性胆汁性胆管炎现有治疗似乎不影响疲劳水平。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patient-reported outcomes (PROs), such as health-related quality of life (HRQL), are important outcome measures for patients with chronic liver diseases (CLDs). Presence of cirrhosis and advanced liver disease have been associated with worsened HRQL and fatigue. On the other hand, some patients with earlier stages of CLD also experience fatigue, causing PRO impairment. Treatment for some CLDs may improve HRQL and, sometimes, levels of fatigue. We aimed to provide an in-depth expert review of concepts related to fatigue and HRQL in patients with primary biliary cholangitis, hepatitis C virus and MASLD (metabolic dysfunction-associated steatotic liver disease). A panel of experts in fatigue and CLD reviewed and discussed the literature and collaborated to provide this expert review of fatigue in CLD. Herein, we review and report on the complexity of fatigue, highlighting that it is comprised of peripheral (neuromuscular failure, often in conjunction with submaximal cardiorespiratory function) and central (central nervous system dysfunction) causes. Fatigue and HRQL are measured using validated self-report instruments. Additionally, fatigue can be measured through objective tests (e.g. grip strength). Fatigue has deleterious effects on HRQL and one's ability to be physically active and socially engaged but does not always correlate with CLD severity. Treatments for hepatitis C virus and MASLD can improve levels of fatigue and HRQL, but current treatments for primary biliary cholangitis do not seem to affect levels of fatigue. We conclude that obtaining PRO data, including on HRQL and fatigue, is essential for determining the comprehensive burden of CLD and its potential treatments.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Kremer AE, Swain MG, et al. Assessment of fatigue and its impact in chronic liver disease. J Hepatol. 2024. PMID: 38670320. doi:10.1016/j.jhep.2024.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。